Search Results

You are looking at 1 - 10 of 246 items for :

  • "interferon" x
  • Refine by Access: All x
Clear All
Full access

Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia Vera

Joan How and Gabriela Hobbs

. Currently, there are also no available therapies that are known to modify the disease and reduce the risk of progression to acute myeloid leukemia (AML) or MF. Interferons are a group of cytokines with immunomodulatory properties and were the first immune

Full access

Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera

Radhika Gangaraju, Soo J. Kim, Jing-Fei Dong, Sabina Swierczek, and Josef T. Prchal

antibiotics, chemotherapy, immunosuppressants, narcotics, and cardiac medications. 6 , 7 We report a case of TTP due to the development of antibodies to ADAMTS13 in association with pegylated interferon alfa-2a (pegIFNa) use in a patient with polycythemia

Full access

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

Michael S. Sabel and Vernon K. Sondak

: 3635 – 3648 . 2 Dickler MN Coit DG Myers ML . Adjuvant therapy of malignant melanoma . Surg Oncol Clin N Am 1997 ; 6 : 793 – 812 . 3 Pfeffer LM Dinarello CA Herberman RB . Biological properties of recombinant alpha-interferons

Full access

Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?

Leslie A. Fecher and Keith T. Flaherty

2004 ; 139 : 961 – 967 . 9 Neuman H Patel A Hanlon C . Stage-IV melanoma and pulmonary metastases: factors predictive of survival . Ann Surg Oncol 2007 ; 14 : 2847 – 2853 . 10 Kirkwood J Strawderman M Ernstoff M . Interferon

Full access

Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients

Paul B. Chapman

analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001 ; 19 : 3622 – 3634 . 2 Kirkwood JM Strawderman MH Ernstoff MS . Interferon alfa-2b adjuvant therapy of high

Full access

The Role of Maintenance Therapy in the Treatment of Multiple Myeloma

Ashraf Z. Badros

patterns vary considerably because of conflicting data about its effectiveness. Currently, NCCN recommends thalidomide (category 1 recommendation) with or without prednisone (category 2B) for maintenance therapy; the roles of interferon and corticosteroids

Full access

Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher K. Bichakjian, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mohammed Kashani-Sabet, Julie R. Lange, Anne Lind, Lainie Martin, Mary C. Martini, Scott K. Pruitt, Merrick I. Ross, Stephen F. Sener, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Jeffrey Weber, and Michael K. Wong

dissection for melanoma . J Clin Oncol 2004 ; 22 : 3677 – 3684 . 70 Cascinelli N Belli F MacKie RM . Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised

Full access

Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

-Dose Interferon The first major randomized trial of adjuvant interferon for completely resected stage III melanoma conducted by the WHO 72 showed no improvement in overall survival (35% for the interferon group vs. 37% for those assigned to observation alone

Full access

Current Issues in Chronic Myeloid Leukemia: Monitoring, Resistance, and Functional Cure

Jorge Cortes, John M. Goldman, and Timothy Hughes

milestones shown in Table 1 with respect to specific time points. 2 - 4 The ELN and NCCN Guidelines recommendations were based largely on response data from the IRIS (International Randomized Study of Interferon and STI571) study, which compared the

Full access

Ten Years of Progress in Renal Cell Carcinoma

Eric Jonasch and Robert J. Motzer

indication. 2 In the next 5 years, bevacizumab plus interferon (IFN) α, 7 pazopanib, 4 and axitinib 5 were also approved. Figure 1 Advances in the treatment of RCC, 2002–2012. Abbreviations: IFN, interferon; OS, overall survival; RCC, renal cell